CohBar, Inc.’s CEO Simon Allen to Present at the 9th Annual Biotech Showcase in San Francisco
MENLO PARK, Calif.--(BUSINESS WIRE)-- CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the Company will present at the 9th Annual Biotech Showcase Conference in San Francisco on Wednesday, January 11th, 2017 at 2:30pm Pacific Time. CohBar’s Chief Executive Officer, Simon Allen, will discuss the Company’s recent announcements about its clinical development program and its ongoing discovery of new biologically active peptides in the mitochondrial genome.
About the Biotech Showcase
Biotech Showcase™ is an investor
and partnering conference devoted to providing private and public
biotechnology and life sciences companies with an opportunity to present
to, and meet with, investors and pharmaceutical executives in one place
concurrently with the J.P. Morgan Healthcare Conference, one of the
industry's largest annual healthcare investor conferences. Investors and
biopharmaceutical executives from around the world gather in San
Francisco during this critical week, which is widely viewed as setting
the tone for the coming year.
About CohBar’s Clinical Development Program
CohBar’s lead
clinical development program is based on MOTS-c, a mitochondrial-derived
peptide discovered in 2012 by the Company’s founders and their academic
collaborators, whose research has shown that MOTS-c plays a significant
role in the regulation of metabolism. The Company has developed
optimized analogs of the MOTS-c peptide, CB4209 and CB4211, as drug
candidates for advancement into IND-enabling activities. These drug
candidates have demonstrated significant therapeutic potential in
preclinical models for the treatment of obesity, with additional ongoing
studies to determine their therapeutic potential for the treatment of
nonalcoholic steatohepatitis (NASH), an advanced form of fatty liver
disease, and as an add-on to other drugs for the treatment of Type-2
diabetes.
About CohBar
CohBar (OTCQX: CWBR and TSXV: COB.U) is a
preclinical stage biotechnology company focused on the research and
development of mitochondria based therapeutics (MBTs), an emerging class
of drugs for the treatment of age-related diseases. MBTs originate from
the discovery by CohBar’s founders of a novel group of peptides within
the mitochondrial genome, which regulate metabolism and cell death and
whose biological activity declines with age. CohBar’s efforts focus on
the development of these mitochondrial-derived peptides (MDPs) into
clinically relevant MBTs that offer the potential to address a broad
range of age-related diseases, including obesity, fatty liver disease,
Type-2 diabetes, cancer, cardiovascular and neurodegenerative disorders.
To date, the Company and its founders have discovered more than 50
biologically active mitochondrial peptides.
Forward-Looking Statements
This news release contains
forward-looking statements, including statements concerning the
company’s plans and prospects, including statements regarding potential
development of MBTs into disease therapeutics. These forward-looking
statements involve a number of risks and uncertainties including the
possibility of unfavorable research results and CohBar’s ability to
obtain capital, retain key personnel, expand its research operations,
and successfully advance its drug discovery and development
programs. Additional assumptions, risks and uncertainties are described
in detail in our registration statements, reports and other filings with
the Securities and Exchange Commission and applicable Canadian
securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of future
performance and that our actual results may differ materially from those
set forth in the forward-looking statements. The forward-looking
statements and other information contained in this news release are made
as of the date hereof and CohBar does not undertake any obligation to
update publicly or revise any forward-looking statements or information,
whether as a result of new information, future events or otherwise,
unless so required by applicable securities laws. Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is defined
in the policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For additional company information, please visit www.cohbar.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170110006487/en/
Investor and Media Contact:
CohBar, Inc.
Anna Schram,
650-446-7888 ext. 114
anna.schram@cohbar.com
Source: CohBar, Inc.
Released January 10, 2017